Literature DB >> 8041899

Radiation dose heterogeneity in receptor and antigen mediated boron neutron capture therapy.

T Hartman1, J Carlsson.   

Abstract

Boron neutron capture therapy, BNCT, might be a valuable tumour therapeutical modality for the treatment of cells that are difficult to handle with conventional methods such as surgery or external radiotherapy. The principle is that tumour associated 10B atoms capture thermal neutrons and thereby forms high-LET helium and lithium ions as reaction products. An interesting development is to conjugate 10B atoms to macromolecules that bind to tumour cells with over-expressed receptors or specific antigens. The targeting macromolecules might be receptor-ligands, antibodies or antibody-fragments containing 10B. The present study deals with the limitations of such an approach. One problem is the background dose from capture of neutrons in physiologically occurring elements, especially nitrogen. We showed, with computer simulations, that the background specific energy (the stochastic analogy of dose) in the cell nuclei, due to captures in nitrogen, had a wide spread and could be rather high, up to 3 Gy in some cells, when relevant neutron fluencies were applied. The maximal amount of 10B that can be delivered to single tumour cells due to receptor-ligand, receptor-antibody or antigen-antibody mediated binding is probably in the range 10(8)-10(10) atoms/cell. Our calculations showed that the tumour cells had to contain about 10(9) 10B/cell to give a therapeutically interesting dose to the nuclei of the targeted cells. The doses were highest when the boron was in the cell nucleus. There was also a wide spread of specific energy absorbed by the nuclei after neutron capture in 10B. When, for example, 10(8) 10(10)B/nucleus were applied the specific energy to the analysed nuclei varied from 0 Gy up to about 7 Gy. These variations were due to the stochastic nature of the capture processes. Some helium or lithium ion tracks passed through the centre of the cell nuclei delivering a lot of energy, some passed through only a smaller part delivering small amounts of energy and sometimes the nuclei escaped without any hits at all. The results were obtained when relevant neutron fluencies (2-5 x 10(12) n/cm2) were applied. Increased neutron fluencies gave higher doses both due to capture in boron and in nitrogen but in order to improve the ratio between the dose to targeted tumour cells and the dose to normal cells, the number of 10B atoms in the targeted cells had to be increased and/or the boron placed in the cell nuclei.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8041899     DOI: 10.1016/0167-8140(94)90414-6

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  9 in total

Review 1.  Chemistry and biology of some low molecular weight boron compounds for boron neutron capture therapy.

Authors:  S Sjöberg; J Carlsson; H Ghaneolhosseini; L Gedda; T Hartman; J Malmquist; C Naeslund; P Olsson; W Tjarks
Journal:  J Neurooncol       Date:  1997-05       Impact factor: 4.130

2.  Toward a cancer therapy with boron-rich oligomeric phosphate diesters that target the cell nucleus.

Authors:  A Nakanishi; L Guan; R R Kane; H Kasamatsu; M F Hawthorne
Journal:  Proc Natl Acad Sci U S A       Date:  1999-01-05       Impact factor: 11.205

Review 3.  Ligand liposomes and boron neutron capture therapy.

Authors:  Jörgen Carlsson; Erika Bohl Kullberg; Jacek Capala; Stefan Sjöberg; Katarina Edwards; Lars Gedda
Journal:  J Neurooncol       Date:  2003 Mar-Apr       Impact factor: 4.130

4.  Remarkable Boron Delivery Of iRGD-Modified Polymeric Nanoparticles For Boron Neutron Capture Therapy.

Authors:  Jiejian Chen; Qiyao Yang; Minchen Liu; Mengting Lin; Tiantian Wang; Zhentao Zhang; Xincheng Zhong; Ningning Guo; Yiying Lu; Jing Xu; Changsheng Wang; Min Han; Qichun Wei
Journal:  Int J Nanomedicine       Date:  2019-10-08

5.  Therapeutic nucleus-access BNCT drug combined CD47-targeting gene editing in glioblastoma.

Authors:  Jiejian Chen; Qi Dai; QiYao Yang; Xiaoyan Bao; Yi Zhou; Haiqing Zhong; Linjie Wu; Tiantian Wang; Zhicheng Zhang; Yiying Lu; Zhentao Zhang; Mengting Lin; Min Han; Qichun Wei
Journal:  J Nanobiotechnology       Date:  2022-03-04       Impact factor: 10.435

Review 6.  Radionuclide carriers for targeting of cancer.

Authors:  Stavroula Sofou
Journal:  Int J Nanomedicine       Date:  2008

Review 7.  Peptide-Drug Conjugates and Their Targets in Advanced Cancer Therapies.

Authors:  Paul Hoppenz; Sylvia Els-Heindl; Annette G Beck-Sickinger
Journal:  Front Chem       Date:  2020-07-07       Impact factor: 5.221

8.  Enlargement of a Modular System-Synthesis and Characterization of an s-Triazine-Based Carboxylic Acid Ester Bearing a Galactopyranosyl Moiety and an Enormous Boron Load.

Authors:  Martin Kellert; Peter Lönnecke; Bernd Riedl; Johannes Koebberling; Evamarie Hey-Hawkins
Journal:  Molecules       Date:  2019-09-10       Impact factor: 4.411

9.  Boron rich nanotube drug carrier system is suited for boron neutron capture therapy.

Authors:  Fabian Heide; Matthew McDougall; Candice Harder-Viddal; Roy Roshko; David Davidson; Jiandong Wu; Camila Aprosoff; Aniel Moya-Torres; Francis Lin; Jörg Stetefeld
Journal:  Sci Rep       Date:  2021-07-30       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.